Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours

Next Previous
Search
Trial Profile

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Atezolizumab (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary) ; Inobrodib (Primary) ; Olaparib (Primary) ; Prednisolone; Prednisone
  • Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors CellCentric

    • Most Recent Events

    • 17 Jul 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2024.
    • 17 Jul 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
    • 04 Jun 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top